產品中心
相關產品
一抗
英文名稱 Anti-BCL9
中文名稱： B淋巴細胞淋巴瘤因子9抗體
別 名 B-cell CLL/lymphoma 9; BCL 9; BCL-9; DLNB11; Legless homolog; B-cell CLL/lymphoma 9-like; LGS; BCL9_HUMAN.
濃 度 1mg/1ml
規 格 0.2ml/200μg
抗體來源 Rabbit
克隆類型 polyclonal
交叉反應 Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Horse, Rabbit, Sheep
產品類型 一抗
研究領域 腫瘤 細胞生物 染色質和核信號 轉錄調節因子 淋巴細胞 b-淋巴細胞
蛋白分子量 predicted molecular weight: 149kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated synthetic peptide derived from human BCL9
亞 型 IgG
純化方法 affinity purified by Protein A
儲 存 液 Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4
產品應用 WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500
（石蠟切片需做抗原修復）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產品介紹 Bcl-9L is a 1,499 amino acid protein that localizes to the nucleus and contains a specialized C-terminal domain that is important for its overall activity. Expressed in breast tissue, as well as in eye, lung, prostate and various carcinomas, Bcl-9L functions as a transcriptional activator that forms a complex with Parafibromin and β-catenin and is thought promote the transcriptional activity of Parafibromin and enhance the neoplastic transforming activity of β-catenin. Bcl-9L exists as multiple alternatively spliced isoforms and is thought to be involved in tumorigenesis, possibly playing a role in tumor transformation and metastasis. The gene encoding Bcl-9L maps to human chromosome 11, which houses over 1,400 genes and comprises nearly 4% of the human genome. Jervell and Lange-Nielsen syndrome, Jacobsen syndrome, Niemann-Pick disease, hereditary angioedema and Smith-Lemli-Opitz syndrome are associated with defects in genes that maps to chromosome 11.
Function : BCL9 is involved in signal transduction through the Wnt pathway. It promotes beta-catenin's transcriptional activity. BCL9 is associated with B-cell acute lymphoblastic leukemia. The overexpression of BCL9 may be of pathogenic significance in B-cell malignancies (referenced from swissprot and entrez gene).
Subunit : Binds to beta-catenin (CTNNB1), PYGO1 and PYGO2.
Subcellular Location : Nuclear
Tissue Specificity : Detected at low levels in thymus, prostate, testis, ovary and small intestine, and at lower levels in spleen, colon and blood.
Post-translational modifications : Phosphorylated upon DNA damage, probably by ATM or ATR.
DISEASE : Note=A chromosomal aberration involving BCL9 is found in a patient with precusor B-cell acute lymphoblastic leukemia (ALL). Translocation t(1;14)(q21;q32). This translocation leaves the coding region intact, but may have pathogenic effects due to alterations in the expression level of BCL9. Several cases of translocations within the 3'-UTR of BCL9 have been found in B-cell malignancies.
Similarity : Belongs to the BCL9 family.
Database links : UniProtKB/Swiss-Prot: O00512.4
中文名稱： B淋巴細胞淋巴瘤因子9抗體
別 名 B-cell CLL/lymphoma 9; BCL 9; BCL-9; DLNB11; Legless homolog; B-cell CLL/lymphoma 9-like; LGS; BCL9_HUMAN.
詳細介紹：
濃 度 1mg/1ml
規 格 0.2ml/200μg
抗體來源 Rabbit
克隆類型 polyclonal
交叉反應 Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Horse, Rabbit, Sheep
產品類型 一抗
研究領域 腫瘤 細胞生物 染色質和核信號 轉錄調節因子 淋巴細胞 b-淋巴細胞
蛋白分子量 predicted molecular weight: 149kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated synthetic peptide derived from human BCL9
亞 型 IgG
純化方法 affinity purified by Protein A
儲 存 液 Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4
產品應用 WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500
（石蠟切片需做抗原修復）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
相關資料：
產品介紹 Bcl-9L is a 1,499 amino acid protein that localizes to the nucleus and contains a specialized C-terminal domain that is important for its overall activity. Expressed in breast tissue, as well as in eye, lung, prostate and various carcinomas, Bcl-9L functions as a transcriptional activator that forms a complex with Parafibromin and β-catenin and is thought promote the transcriptional activity of Parafibromin and enhance the neoplastic transforming activity of β-catenin. Bcl-9L exists as multiple alternatively spliced isoforms and is thought to be involved in tumorigenesis, possibly playing a role in tumor transformation and metastasis. The gene encoding Bcl-9L maps to human chromosome 11, which houses over 1,400 genes and comprises nearly 4% of the human genome. Jervell and Lange-Nielsen syndrome, Jacobsen syndrome, Niemann-Pick disease, hereditary angioedema and Smith-Lemli-Opitz syndrome are associated with defects in genes that maps to chromosome 11.
Function : BCL9 is involved in signal transduction through the Wnt pathway. It promotes beta-catenin's transcriptional activity. BCL9 is associated with B-cell acute lymphoblastic leukemia. The overexpression of BCL9 may be of pathogenic significance in B-cell malignancies (referenced from swissprot and entrez gene).
Subunit : Binds to beta-catenin (CTNNB1), PYGO1 and PYGO2.
Subcellular Location : Nuclear
Tissue Specificity : Detected at low levels in thymus, prostate, testis, ovary and small intestine, and at lower levels in spleen, colon and blood.
Post-translational modifications : Phosphorylated upon DNA damage, probably by ATM or ATR.
DISEASE : Note=A chromosomal aberration involving BCL9 is found in a patient with precusor B-cell acute lymphoblastic leukemia (ALL). Translocation t(1;14)(q21;q32). This translocation leaves the coding region intact, but may have pathogenic effects due to alterations in the expression level of BCL9. Several cases of translocations within the 3'-UTR of BCL9 have been found in B-cell malignancies.
Similarity : Belongs to the BCL9 family.
Database links : UniProtKB/Swiss-Prot: O00512.4
- 上一條：腫瘤轉移抑制蛋白BAMBI抗體
- 下一條：蛋白BOC抗體
